OOIR: Observatory of International Research

Papers

(The TQCC of British Journal of Haematology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	101
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation	93
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma	92
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry	89
Updates on targeted therapies for acute myeloid leukaemia	82
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience	81
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients	78
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies	76
Disseminated intravascular coagulation: epidemiology, biomarkers, and management	76
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations	73
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination	71
Impact of COVID‐19 on red blood cell rheology	69
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy	67
Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series	66
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity	65
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma	65
Guidelines on the use of irradiated blood components	62
Emicizumab treatment and monitoring in a paediatric cohort: real‐world data	62
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?	57
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy	56
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies	55
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies	52
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	52
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience	51
MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a pros	50

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye	50
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients	50
COVID‐19 mortality in patients on anticoagulants and antiplatelet agents	49
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients	49
Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐19	48
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant	46
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold	46
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia	45
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells	45
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations	45
ABO phenotype and death in critically ill patients with COVID‐19	44
COVID‐19 and immunothrombosis: emerging understanding and clinical management	44
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres	44
Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes	43
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study	42
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study	42
Convalescent plasma for persisting COVID‐19 following therapeutic lymphocyte depletion: a report of rapid recovery	41
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis	41
A left shift in the oxyhaemoglobin dissociation curve in patients with severe coronavirus disease 2019 (COVID‐19)	40
Haematological management of major haemorrhage: a British Society for Haematology Guideline	39
Secondary HLH is uncommon in severe COVID‐19	38
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia	38
Thrombophilia testing: A British Society for Haematology guideline	37
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	36
Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia	36
Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders	36
C1 esterase inhibitor and the contact system in COVID‐19	35
Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort s	35
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches	35
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries	35
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome	34
Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood	34
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	34
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline	34
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials	34
The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper	34
Anti‐A isohaemagglutinin titres and SARS‐CoV‐2 neutralization: implications for children and convalescent plasma selection	34
Identification of CXCL12‐abundant reticular cells in human adult bone marrow	34
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine	34
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy	33
Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges	33
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients	33
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion	33
Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flo	32
Thrombosis in immune thrombocytopenia — current status and future perspectives	32
Application of the LymphGen classification tool to 928 clinically and genetically‐characterised cases of diffuse large B cell lymphoma (DLBCL)	32
p53 is associated with high‐risk and pinpointsTP53missense mutations in mantle cell lymphoma	32
Ruxolitinib for tocilizumab‐refractory severe COVID‐19 infection	32
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics	31
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience	31

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival	31
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia	31
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity	31
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	31
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)	31
Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience	30
Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline	30
Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome	29
Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children	29
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future	29
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) wi	29
Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide	29
Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms	28
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients	28
Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease	28
von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate‐to‐severe COVID‐19 patients	28
Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation	28
Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trial	28
Impact of major bleeding and thrombosis on 180‐day survival in patients with severe COVID‐19 supported with veno‐venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observa	27
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study	27
A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation	26
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute pro	26
Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study	26
Are mushroom‐shaped erythrocytes an indicator of COVID‐19?	26
Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date	26
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination	25
COVID‐19 associated Kikuchi‐Fujimoto disease	25
Varying presentations and favourable outcomes of COVID‐19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases	25
Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease	25
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study	25
Vasculo‐toxic and pro‐inflammatory action of unbound haemoglobin, haem and iron in transfusion‐dependent patients with haemolytic anaemias	24
Current and future therapies for haemophilia—Beyond factor replacement therapies	24
Second primary malignancy in myelofibrosis patients treated with ruxolitinib	24
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline	24
Effect of low or high doses of low‐molecular‐weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID‐19	24
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients	24
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study	24
Abnormal concentration of porphyrins in serum from COVID‐19 patients	24
The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma	24
Absence of hydroxyurea‐induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia	23
COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience	23
Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma	23
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy	23
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuita	23
The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma	23
Direct‐acting antiviral agents for hepatitis C virus‐mixed cryoglobulinaemia: dissociated virological and haematological responses	22
Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities	22
Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab	22
Thrombolysis restores perfusion in COVID‐19 hypoxia	22
Adoptive immunotherapy with double‐bright (CD56^bright/CD16^bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concep	22
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study	21
Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients	21
Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features	21
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before	21
First use of the anti‐VWF nanobody caplacizumab to treat iTTP in pregnancy	21
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy	21
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma	21
The NICE COVID‐19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact	20
Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	20
Safety of anti‐SARS‐CoV‐2 vaccination for patients with immune thrombocytopenia	20
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia	20
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita	20
Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study	20
The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm	20
Novel therapies for immune thrombocytopenia	20
Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres	20
Plasma microparticles of intubated COVID‐19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine‐dependent manner	20
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma	20
Co‐morbidities and mortality associated with transfusion‐dependent beta‐thalassaemia in patients in England: a 10‐year retrospective cohort analysis	20
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura	20
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders	20
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial	20
Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7	20
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection	20
Efficacy and safety of intravitreal methotrexate for vitreo‐retinal lymphoma – 20 years of experience	20
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*	20
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant	19
Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies	19
Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results	19
Guideline for the first‐line management of Classical Hodgkin Lymphoma — A British Society for Haematology guideline	19

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study	19
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report	18
Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021	18
Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia	18
Rapid screening of COVID‐19 patients using white blood cell scattergrams, a study on 381 patients	18
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies	18
Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline	18
Haemophilia: factoring in new therapies	18
Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance	18
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses	18
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent	18
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico‐biological parameters	18
Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia	18
Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency	18
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia	18
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia	18
Combined IL‐6 and JAK/STAT inhibition therapy in COVID‐19‐related sHLH, potential game changer	17
Front‐line management of post‐transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline	17
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic	17
Gene therapy for primary immunodeficiencies	17
Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID‐19 in immunocompromised patients	17
Unanswered questions in cancer‐associated thrombosis	17
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019	17
EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features	17
Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia	17
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure	17
Early integration of palliative care for patients with haematological malignancies	17
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with si	17
Molecular dynamics of targeting CD38 in multiple myeloma	16
Heterogeneity in reporting venous thromboembolic phenotypes in COVID‐19: methodological issues and clinical implications	16
Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma	16
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients	16
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	16
Deficient mitophagy pathways in sickle cell disease	16
Measurement of long‐term iron absorption and loss during iron supplementation using a stable isotope of iron (⁵⁷Fe)	16
Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation	16
SLN124, a GalNac‐siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron‐overload in a mouse model of β‐thalassaemi	16
Progress in treating chronic granulomatous disease	16
Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL‐V)	16
Venetoclax plus hypomethylating agent in blast‐phase myeloproliferative neoplasm: preliminary experience with 12 patients	16
Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response	16
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series	16
A case of severe aplastic anaemia after SARS‐CoV‐2 vaccination	16
Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation	16
Oncolytic herpes simplex virus type 1 (HSV‐1) in combination with lenalidomide for plasma cell neoplasms	15
Haemoglobin response to senicapoc in patients with sickle cell disease: a re‐analysis of the Phase III trial	15
Role of bone marrow‐derived mesenchymal stem cell defects in CD8⁺CD28^– suppressor T‐lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms	15
Maternal and neonatal outcomes in 80 patients diagnosed with non‐Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy	15
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine	15
Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases	15
Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo	15
Alpha‐defensins: risk factor for thrombosis in COVID‐19 infection	15
The use of frailty assessments in treating older adults with aggressive lymphomas	15
Monocyte–macrophage polarization and recruitment pathways in the tumour microenvironment of B‐cell acute lymphoblastic leukaemia	15
Viral hepatitis in haemophilia: historical perspective and current management	15
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies	15
Mitochondria transfer from early stages of erythroblasts to their macrophage niche via tunnelling nanotubes	15
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up	15
The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b2	15
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma	15
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia	15
Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant	15
Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma	15
Transfusion management of severe anaemia in African children: a consensus algorithm	15
Liquid biopsy: a non‐invasive approach for Hodgkin lymphoma genotyping	15
The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies	15
Management of cardiovascular complications of bruton tyrosine kinase inhibitors	15
Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart rev	15
Sickle cell disease: progress towards combination drug therapy	15
Saving lives through early diagnosis: the promise and role of point of care testing for sickle cell disease	15
The wider perspective: cord blood banks and their future prospects	15
Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma	15
Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID‐19 while we are awaiting the results of clinical trials?	15
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity	14
Guideline for the treatment of chronic lymphocytic leukaemia	14
British Society for Haematology Guidelines on transfusion for fetuses, neonates and older children (Br J Haematol. 2016;175:784–828). Addendum August 2020	14
Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia	14
The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma	14
Activation of circulating platelets in vaccine‐induced thrombotic thrombocytopenia and its reversal by intravenous immunoglobulin	14
Controversies in the use of new bone‐modifying therapies in multiple myeloma	14
Reduced‐dose post‐transplant cyclophosphamide plus low‐dose post‐transplant anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis with fludarabine–busulfan–cytarabine conditioning in haploi	14
Anti‐severe acute respiratory syndrome coronavirus‐2 adenoviral‐vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers	14
Down the Rabbit‐Hole of blood groups and COVID‐19	14
Case report: Up‐front allogeneic stem cell transplantation in a patient with the VEXAS syndrome	14
Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study	14
A real‐world study of immune thrombocytopenia management during the COVID‐19 pandemic in the UK	14
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis	14
Screening and monitoring of the BTK^C481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy	14
Circulating cell‐free DNA improves the molecular characterisation of Ph‐negative myeloproliferative neoplasms	14
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐la	14
Cardiovascular disease in hereditary haemophilia: The challenges of longevity	14
Long‐term follow‐up of children with risk organ‐negative Langerhans cell histiocytosis after 2‐chlorodeoxyadenosine treatment	14
Benefits of risk‐adapted and mould‐specific antifungal prophylaxis in childhood leukaemia	14
Characteristic vacuolisation of granulocytic and erythroid precursors associated with VEXAS syndrome	14
COVID‐19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience	14